Inhalational anthrax

Summary

Inhalational anthrax (MONDO:0016595) is a disease and 5 clinical trials. Top therapeutic interventions include obiltoxaximab and ciprofloxacin. A subtype of anthrax infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Phenotypes (HPO): 12
• Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Validated

Signs & symptoms

Clinical features (HPO)

12 HPO clinical features (Orphanet curated; top 12 by frequency):

HPO ID	Term	Frequency
HP:0000971	Abnormality of the sweat gland	Very frequent (80-99%)
HP:0001945	Fever	Very frequent (80-99%)
HP:0011159	Epigastric auras	Very frequent (80-99%)
HP:0012378	Fatigue	Very frequent (80-99%)
HP:0001289	Confusion	Frequent (30-79%)
HP:0002013	Vomiting	Frequent (30-79%)
HP:0002094	Dyspnea	Frequent (30-79%)
HP:0002098	Respiratory distress	Frequent (30-79%)
HP:0002546	Incomprehensible speech	Frequent (30-79%)
HP:0002615	Hypotension	Frequent (30-79%)
HP:0011029	Internal hemorrhage	Frequent (30-79%)
HP:0100806	Sepsis	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	inhalational anthrax
Mondo ID	MONDO:0016595
MeSH	C571912
Orphanet	247257
DOID	DOID:0050160
ICD-10-CM	A22.1
SNOMED CT	11389007
UMLS	C0155866
MedGen	57841
GARD	0020657
MedDRA	10035667
Is cancer (heuristic)	no

Also known as: inhalation anthrax disease · pulmonary anthrax · respiratory anthrax · respiratory anthrax disease

Disease family

This is a subtype of anthrax infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › anthrax infection › inhalational anthrax

Related subtypes (3): gastrointestinal anthrax, cutaneous anthrax, injection anthrax

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01929226	PHASE1	COMPLETED	Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
NCT01932242	PHASE1	COMPLETED	Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
NCT01932437	PHASE1	COMPLETED	Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
NCT01952444	PHASE1	COMPLETED	Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
NCT03569553	Not specified	NOT_YET_RECRUITING	A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OBILTOXAXIMAB	4	4
CIPROFLOXACIN	4	1